/NVCR
NVCR Stock - NovoCure Limited
Healthcare|Medical - Instruments & SuppliesNASDAQ
$12.84+2.23%
+$0.28 (+2.23%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.34
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+227.1%upside
Target: $42.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NVCR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.71 – $12.97
TARGET (TP)$42.00
STOP LOSS$11.81
RISK/REWARD1:28.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$32.05
52W Low$10.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $605.22M | $509.34M | $537.84M | $535.03M | $494.37M |
| Gross Profit | $468.04M | $381.06M | $422.97M | $420.15M | $387.87M |
| Gross Margin | 77.3% | 74.8% | 78.6% | 78.5% | 78.5% |
| Operating Income | $-170,496,000 | $-232,870,000 | $-89,523,000 | $-44,333,000 | $30.40M |
| Net Income | $-168,627,000 | $-207,043,000 | $-92,534,000 | $-58,351,000 | $19.81M |
| Net Margin | -27.9% | -40.6% | -17.2% | -10.9% | 4.0% |
| EPS | $-1.56 | $-1.95 | $-0.88 | $-0.56 | $0.20 |
Company Overview
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
46%
Hold / Neutral
6
46%
Sell / Underperform
1
8%
Analyst Consensus🔴 Bearish
6 Bullish7 Neutral/Bearish
Price Targets
$59
Average Target
↑ 355.6% Upside
Now
$15
Low
$59
Average
$140
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 25th 2025 | Wells Fargo | Downgrade | Equal Weight | $14.5 |
| July 8th 2025 | Ladenburg Thalmann | Initiation | Buy | $30 |
| December 2nd 2024 | Evercore ISI | Upgrade | Outperform | $30← $18 |
| October 16th 2024 | H.C. Wainwright | Upgrade | Buy | $30← $24 |
| November 20th 2023 | JP Morgan | Resumed | Neutral | $15 |
| August 28th 2023 | H.C. Wainwright | Downgrade | Neutral | $25← $85 |
| August 8th 2023 | Piper Sandler | Upgrade | Overweight | $45 |
| August 4th 2023 | SVB Securities | Initiation | Outperform | $51 |
| July 31st 2023 | Evercore ISI | Upgrade | In-line | $33 |
| June 7th 2023 | Wedbush | Upgrade | Neutral | $46← $53 |
| May 16th 2023 | Wells Fargo | Upgrade | Overweight | $104← $70 |
| March 17th 2023 | JP Morgan | Downgrade | Underweight | $50← $99 |
| January 6th 2023 | Wells Fargo | Downgrade | Equal Weight | $107← $89 |
| January 5th 2023 | H.C. Wainwright | Reiterated | Buy | $140← $100 |
| November 29th 2022 | Wells Fargo | Upgrade | Overweight | $89← $74 |
Earnings History & Surprises
NVCRBeat Rate
53%
Last 19 quarters
Avg Surprise
-116.0%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
+15.1%
$-0.45vs$-0.53
Q2 24
+16.3%
$-0.36vs$-0.43
Q3 24
+22.5%
$-0.31vs$-0.40
Q4 24
+17.6%
$-0.28vs$-0.34
Q1 25
-79.4%
$-0.61vs$-0.34
Q2 25
+34.0%
$-0.31vs$-0.47
Q3 25
+7.7%
$-0.36vs$-0.39
Q4 25
+21.4%
$-0.33vs$-0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | $-0.39 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Q3 2025 | Jul 24, 2025 | $-0.39 | $-0.36 | +7.7% | ✓ BEAT |
Q2 2025 | Apr 24, 2025 | $-0.47 | $-0.31 | +34.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.34 | $-0.61 | -79.4% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $-0.40 | $-0.31 | +22.5% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.53 | $-0.45 | +15.1% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $-0.52 | $-0.46 | +11.5% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $-0.50 | $-0.54 | -8.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.36 | $-0.50 | -38.9% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.32 | $-0.36 | -12.5% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $-0.30 | $-0.25 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $-0.14 | $-0.23 | -64.3% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $-0.17 | $-0.04 | +76.5% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.10 | $-0.25 | -150.0% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $-0.06 | $-0.13 | -116.7% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-0.01 | $-0.14 | -1674.4% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | $-0.01 | $-0.04 | -300.0% | ✗ MISS |
Latest News
Novocure Promotes Frank Leonard To Chief Executive Officer Effective Immediately
➖ NeutralBenzinga•Dec 1, 2025, 12:04 PM
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $42
📈 PositiveBenzinga•Oct 30, 2025, 04:35 PM
NovoCure Q3 EPS $(0.33) Beats $(0.42) Estimate, Sales $167.204M Beat $159.189M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 11:01 AM
JP Morgan Maintains Neutral on NovoCure, Lowers Price Target to $23
➖ NeutralBenzinga•Oct 27, 2025, 02:36 PM
Novocure To Present TTFields Data At EANO Prague Oct. 16–19 And ESMO Berlin Oct. 17–21; Highlights Radiosensitization In Glioblastoma And PANOVA-3 Post-Hoc In Pancreatic Cancer
📈 PositiveBenzinga•Oct 15, 2025, 11:02 AM
Novocure To Present Final Results From Phase 3 METIS Trial Of Tumor Treating Fields Therapy For Brain Metastases From NSCLC At 2025 ASTRO
➖ NeutralBenzinga•Sep 29, 2025, 08:32 PM
Japan's Ministry Of Health, Labour And Welfare Approves Novocure's Optune Lua For Concurrent Use With PD-1/PD-L1 Inhibitors For Adult Patients With Unresectable Advanced/Recurrent Non-small Cell Lung Cancer Who Have Progressed On Or After Platinum-Based Chemotherapy
📈 PositiveBenzinga•Sep 15, 2025, 11:03 AM
NovoCure Terminates LUNAR-4 Trial, Decision Not Related To Safety Concerns
📉 NegativeBenzinga•Aug 28, 2025, 11:13 AM
Novocure Expands Access To Tumor Treating Fields Therapy In Spain For Adult Patients With Newly Diagnosed Glioblastoma
📈 PositiveBenzinga•Aug 25, 2025, 11:09 AM
Novocure Submits Premarket Approval Application To The FDA For Tumor Treating Fields Therapy For Locally Advanced Pancreatic Cancer
📈 PositiveBenzinga•Aug 20, 2025, 11:01 AM
Frequently Asked Questions about NVCR
What is NVCR's current stock price?
NovoCure Limited (NVCR) is currently trading at $12.84 per share. The stock has moved +2.23% today.
What is the analyst price target for NVCR?
The average analyst price target for NVCR is $42.00, based on 1 analyst.
What sector is NovoCure Limited in?
NovoCure Limited operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is NVCR's market cap?
NovoCure Limited has a market capitalization of $1.44 billion, making it a small-cap company.
Does NVCR pay dividends?
No, NovoCure Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAZTA
Azenta, Inc.
$34.43
Mkt Cap: $1.6B
BLFS
BioLife Solutions, Inc.
$25.07
Mkt Cap: $1.2B
ESTA
Establishment Labs Holdings Inc.
$74.42
Mkt Cap: $2.2B
EVO
Evotec SE
$2.95
Mkt Cap: $1.0B
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
$27.32
Mkt Cap: $1.6B
NEOG
Neogen Corporation
$7.20
Mkt Cap: $1.6B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
STAA
STAAR Surgical Company
$25.14
Mkt Cap: $1.2B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
Explore stocks similar to NVCR for comparison